Systemic Neutralizing Antibodies Induced by Long Interval Mucosally Primed Systemically Boosted Immunization Correlate with Protection from Mucosal SHIV Challenge

Overview

Journal Virology

Specialty Microbiology

Date 2008 Oct 25

PMID 18947849

Citations 41

Authors

Willy M J M Bogers

David Davis

Ilona Baak

Elaine Kan

Sam Hofman

Yide Sun

Daniella Mortier

Ying Lian

Herman Oostermeijer

Zahra Fagrouch

Rob Dubbes

Martin van der Maas

Petra Mooij

Gerrit Koopman

Ernst Verschoor

Johannes P M Langedijk

Jun Zhao

Egidio Brocca-Cofano

Marjorie Robert-Guroff

Indresh Srivastava

Susan Barnett

Jonathan L Heeney

Affiliations

Soon will be listed here.

Abstract

Immune correlates of vaccine protection from HIV-1 infection would provide important milestones to guide HIV-1 vaccine development. In a proof of concept study using mucosal priming and systemic boosting, the titer of neutralizing antibodies in sera was found to correlate with protection of mucosally exposed rhesus macaques from SHIV infection. Mucosal priming consisted of two sequential immunizations at 12-week intervals with replicating host range mutants of adenovirus type 5 (Ad5hr) expressing the HIV-1(89.6p) env gene. Following boosting with either heterologous recombinant protein or alphavirus replicons at 12-week intervals animals were intrarectally exposed to infectious doses of the CCR5 tropic SHIV(SF162p4). Heterologous mucosal prime systemic boost immunization elicited neutralizing antibodies (Nabs), antibody-dependent cytotoxicity (ADCC), and specific patterns of antibody binding to envelope peptides. Vaccine induced protection did not correlate with the type of boost nor T-cell responses, but rather with the Nab titer prior to exposure.

Citing Articles

Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.

Klasse P, Moore J J Virol. 2022; 96(8):e0003422.

PMID: 35384694 PMC: 9044961. DOI: 10.1128/jvi.00034-22.

A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.

Musich T, Thovarai V, Venzon D, Mohanram V, Tuero I, Miller-Novak L J Virol. 2020; 94(24).

PMID: 32967951 PMC: 7925174. DOI: 10.1128/JVI.01225-20.

Replicating Adenovirus-SIV Immunization of Rhesus Macaques Induces Mucosal Dendritic Cell Activation and Function Leading to Rectal Immune Responses.

Ko E, Hait S, Enyindah-Asonye G, Rahman M, Hoang T, Robert-Guroff M Front Immunol. 2019; 10:779.

PMID: 31031768 PMC: 6473464. DOI: 10.3389/fimmu.2019.00779.

Survivors Remorse: antibody-mediated protection against HIV-1.

Lewis G, Pazgier M, DeVico A Immunol Rev. 2017; 275(1):271-284.

PMID: 28133809 PMC: 5642910. DOI: 10.1111/imr.12510.

Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.

Thomas M, Nyanhete T, Tuero I, Venzon D, Robert-Guroff M PLoS One. 2016; 11(7):e0158505.

PMID: 27391605 PMC: 4938603. DOI: 10.1371/journal.pone.0158505.

References

Amara R, Villinger F, Altman J, Lydy S, ONeil S, Staprans S . Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292(5514):69-74. DOI: 10.1126/science.1058915. View

Ahmad A, Morisset R, Thomas R, Menezes J . Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr (1988). 1994; 7(5):428-37. View

Seaman M, LeBlanc D, Grandpre L, Bartman M, Montefiori D, Letvin N . Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology. 2007; 367(1):175-86. PMC: 2075526. DOI: 10.1016/j.virol.2007.05.024. View

Patterson L, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B . Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol. 2003; 77(16):8607-20. PMC: 167211. DOI: 10.1128/jvi.77.16.8607-8620.2003. View

Polacino P, Stallard V, Montefiori D, Brown C, Richardson B, Morton W . Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol. 1999; 73(4):3134-46. PMC: 104075. DOI: 10.1128/JVI.73.4.3134-3146.1999. View

Robert-Guroff M, Kaur H, Patterson L, Leno M, Conley A, McKenna P . Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol. 1998; 72(12):10275-80. PMC: 110613. DOI: 10.1128/JVI.72.12.10275-10280.1998. View

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

Harouse J, Gettie A, Tan R, Blanchard J, Cheng-Mayer C . Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 1999; 284(5415):816-9. DOI: 10.1126/science.284.5415.816. View

Li M, Gao F, Mascola J, Stamatatos L, Polonis V, Koutsoukos M . Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005; 79(16):10108-25. PMC: 1182643. DOI: 10.1128/JVI.79.16.10108-10125.2005. View

10.

Caley I, Betts M, Irlbeck D, Davis N, Swanstrom R, Frelinger J . Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol. 1997; 71(4):3031-8. PMC: 191432. DOI: 10.1128/JVI.71.4.3031-3038.1997. View

11.

Bogers W, Niphuis H, ten Haaft P, Laman J, Koornstra W, Heeney J . Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS. 1995; 9(12):F13-8. View

12.

Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M . Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2004; 79(2):771-9. PMC: 538538. DOI: 10.1128/JVI.79.2.771-779.2005. View

13.

Burton D, Desrosiers R, Doms R, Koff W, Kwong P, Moore J . HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004; 5(3):233-6. DOI: 10.1038/ni0304-233. View

14.

Mossman S, Bex F, Berglund P, Arthos J, ONeil S, Riley D . Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol. 1996; 70(3):1953-60. PMC: 190024. DOI: 10.1128/JVI.70.3.1953-1960.1996. View

15.

Perri S, Greer C, Thudium K, Doe B, Legg H, Liu H . An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003; 77(19):10394-403. PMC: 228391. DOI: 10.1128/jvi.77.19.10394-10403.2003. View

16.

Mooij P, Balla-Jhagjhoorsingh S, Koopman G, Beenhakker N, van Haaften P, Baak I . Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol. 2008; 82(6):2975-88. PMC: 2258966. DOI: 10.1128/JVI.02216-07. View

17.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

18.

Nixon D, Broliden K, Ogg G, Broliden P . Cellular and humoral antigenic epitopes in HIV and SIV. Immunology. 1992; 76(4):515-34. PMC: 1421556. View

19.

Srivastava I, Stamatatos L, Legg H, Kan E, Fong A, Coates S . Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol. 2002; 76(6):2835-47. PMC: 135955. DOI: 10.1128/jvi.76.6.2835-2847.2002. View

20.

Gomez-Roman V, Florese R, Patterson L, Peng B, Venzon D, Aldrich K . A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2005; 308(1-2):53-67. DOI: 10.1016/j.jim.2005.09.018. View